Vildagliptin: An inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

Expert Opinion on Investigational Drugs

Volumn 15, Issue 4, 2006, Pages 431-442

  Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

DPP 4; GLP 1; Glycaemic control; Type 2 diabetes; Vildagliptin

Indexed keywords

6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

AREA UNDER THE CURVE; ARTICLE; BURSITIS; CELL FUNCTION; CLINICAL TRIAL; COUGHING; DIET RESTRICTION; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; GLUCAGON RELEASE; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INHIBITION KINETICS; INSULIN RESISTANCE; MONKEY; MOUSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; POSTPRANDIAL STATE; PROTEIN DEGRADATION; PRURITUS; RAT; RHINOPHARYNGITIS; SATIETY; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION;

ADAMANTANE; ADENOSINE DEAMINASE; ANIMALS; ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; ISOENZYMES;

EID: 33645707285     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.4.431     Document Type: Article

References (73)

1. WILD S, ROGLIC C, GREEN A, SICREE R, KING H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes (2004) 27:1047-1053.
2. TURNER RC: The UK Prospective Diabetes Study: a review. Diabetes Care (1998) 21(Suppl. 3):C35-C38.
3. LEAHY JL: Pathogenesis of Type 2 diabetes mellitus. Arch. Med. Res. (2005) 36:197-209.
4. AHRÉN B, PACINI G: Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess β cell function in clinical studies. Eur. J. Endocrinol. (2004) 150:97-104.
5. DUNNING BE, FOLEY JE, AHRÉN B: α cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia (2005) 48:1700-1713.
6. DENG S, VATAMANIUK M, HUANG X et al.: Structural and functional abnormalities in the islets isolated from Type 2 diabetic subjects. Diabetes (2004) 53:624-632.
7. BUTLER AE, JANSON J, BONNER-WEIR S, RITZEL R, RIZZA RA, BUTLER PC: β-cell deficit and increased β-cell apoptosis in humans with Type 2 diabetes. Diabetes (2003) 52:102-110.
8. AHRÉN B: Type 2 diabetes, insulin secretion and β-cell mass. Curr. Mol. Med. (2005) 5:275-286.
9. INZUCCHI SE: Oral antihyperglycemia therapy for Type 2 diabetes: scientific review. J. Am. Med. Assoc. (2002) 287:360-372.
10. RENDELL M: The role of sulphonylurea in the management of Type 2 diabetes mellitus. Drugs (2004) 64:1339-1358.
11. DIAMANT M, HEINE RJ: Thiazolidinediones in Type 2 diabetes mellitus: current clinical evidence. Drugs (2003) 63:1373-1405.
12. SHAW RJ, LAMIA KA, VASQUEZ D et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 310:1642-1646.
13. HSIA SH, DAVIDSON MB: Established therapies for diabetes mellitus. Curr. Med. Res. Opin. (2002) 18(Suppl. 1):S13-S21.
14. NOURPAVAR A, BULOTTA A, DI MARIO U, PERFETTI R: Novel strategies for pharmacological management of Type 2 diabetes. Trends Pharmacol. Sci. (2004) 25:86-91.
15. AHRÉN B, SCHMITZ O: GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of Type 2 diabetes. Horm. Metab. Res. (2004) 36:867-876.
16. DEACON CF: Therapeutic strategies based on glucagon-like peptide-1. Diabetes (2004) 53:2181-2189.
17. AHRÉN B: Enhancement or prolongation of GLP-1 activity as a strategy for treatment of Type 2 diabetes. Drug Discov. Today (2004) 1:207-212.
18. DEACON CF, AHRÉN B, HOLST JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? Expert Opin. Investig. Drugs (2004) 13:1091-1102.
19. AHRÉN B: Inhibition of dipeptidyl peptidase-4 (DPP-4) - a novel approach to treat Type 2 diabetes. Curr. Enzyme Inhibition (2005) 1:65-74.
20. McINTOSH CHS, DEMUTH HU, POSPISILIK JA, PEDERSON R: Dipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents? Regul. Pept. (2005) 128:159-165.
21. DRUCKER DJ: Enhancing incretin action for the treatment of Type 2 diabetes. Diabetes Care (2003) 26:2929-2940.
22. HOLST JJ, GROMADA J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am. J. Physiol. (2004) 287:E199-E206.
23. PERFETTI R, HUI H: The role of GLP-1 in the life and death of pancreatic β cells. Horm. Metab. Res. (2004) 36:804-810.
24. STOFFERS DA: The development of β-cell mass: recent progress and potential role of GLP-1. Horm. Metab. Res. (2004) 36:811-821.
25. NYSTRÖM T, GUTNIAK MK, ZHANG Q et al.: Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. (2004) 287:E1209-E1215.
26. AHRÉN B: Exenatide: a novel treatment of Type 2 diabetes. Therapy (2005) 2:207-222.
27. DEACON CF: What do we know about the secretion and degradation of incretin hormones? Regul. Pept. (2005) 128:117-124.
28. DEACON CF, NAUCK MA, TOFT-NIELSEN M-B, PRIDAL L, WILLMS B, HOLST JJ: Both subcutaneously and intravenously, administered glucagon-like peptide-1 are rapidly degraded from the amino-acid terminus in Type 2 diabetic patients and in healthy subjects. Diabetes (1995) 44:1126-1131.
29. HOLST JJ, DEACON CF: Inhibition of the activity of dipeptidyl peptidase IV as a treat-ment for Type 2 diabetes. Diabetes (1998) 47:1663-1670.
30. MARGUET D, BAGGIO L, KOBAYASHI T et al.: Enhanced secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA (2000) 97:6874-6879.
31. NAGAKURA T, YASUDA N, YAMAZAKI K et al.: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. Biochem. Biophys. Res. Commun. (2001) 284:501-506.
32. PEDERSON RA, WHITE HA, SCHLENZIG D, PAULY RP, McINTOSH CH, DE-MUTH HU: Improved glucose tolerance in Zucker rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazlodide. Diabetes (1998) 47:1253-1258.
33. BALKAN B, KWASNIK L, MISERENDINO R, HOLST JJ, LI X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36) amide concentrations and improves oral glucose trolerance in obese Zucker rats. Diabetologia (1999) 42:1324-1331.
34. AHRÉN B, HOLST JJ, MÅRTENSSON H, BALKAN B: Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur. J. Pharmacol. (2000) 404:239-245.
35. POSPISILIK JA, STAFFORD SG, DEMUTH HU et al.: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/09 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia and β-cell responsiveness in VDF (fa/fa) Zucker rats. Diabetes (2002) 51:943-950.
36. AHRÉN B, SIMONSSON E, LARSSON H et al.: Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in Type 2 diabetes. Diabetes Care (2002) 25:869-875.
37. KIM D, WANG L, BECONI M et al.: (2R)-4-oxo-4-[3-trifluoromethyl)-5,6-dihyd ro[1,2,4]triazolo[4,3-α]pyrazin-7(8H)-y1]-1 -(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48:141-151.
38. AUGERI DJ, ROBL JA, BETEBENNER DA et al.: Discovery and preclinical profile of saxagliptin (BMS-47118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of Type 2 diabetes. J. Med. Chem. (2005) 48:5025-5037.
39. VILLHAUER EB, BRINKMAN JA, NADERI GB et al.: 1- [[(3-hydroxy-1-adman-tyl)amino]acetyl]-2-cyano-(S) pyrrolidine: a potent, selective and orally bioavailable di-peptidyl peptidase IV inhibitor with antihyperglycemia properties. J. Med. Chem. (2003) 46:2774-2789.
40. BARLOCCO D: LAF-237. Curr. Opin. Invest. Drugs (2004) 5:1091-1100.
41. BRANDT I, JOOSSENS J, CHEN X et al.: Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vil-dagliptin ((2S)- (3-hydroxyadaman tan-1-yl)amino] acetyl]-pyrrolidine-2-carbonitrile). Biochem. Pharmacol. (2005) 70:134-143.
42. LANKAS G, LEITING B, ROY RS et al.: Dipeptidyl peptidase IV inhibition for the treatment of Type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes (2005) 54:2988-2994.
43. AHRÉN B, LANDIN-OLSSON M, JANSSON PA, SVENSSON M, HOLMES D, SCHWEIZER A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in Type 2 diabetes. J. Clin. Endocrinol. Metab. (2004) 89:2078-2084.
44. BURKEY BF, LI X, BOLOGNESE KL et al.: Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats. J. Pharmacol. Exptl. Ther. (2005) 315:688-695.
45. MIKA A, STASHIKO M, LUBBEN T et al.: Acute DPP IV inhibition minimizes glucose and insulin responses to a glucose challenge in a diabetic mouse. Diabetes (2003) 52(Suppl. 1):A350.
46. ROLIN B, NYGAARD H, WILKEN M, KANSTRUP AB, CAAR RD: The novel xanthine-based DPPIV inhibitor NN7201 and LAF237 improve glucose tolerance, but do not prevent progression of diabetes in Zucker diabetic fatty rats. Diabetes (2004) 53(Suppl. 2):A341.
47. SÖRHEDE WINZELL M, AHRÉN B: The high-fat fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and Type 2 diabetes. Diabetes (2004) 53(Suppl. 3):S215-S219.
48. DARDIK B, VALENTIN M, SCHWARZTKOPF C et al.: NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant cynomolgus monkeys. Diabetes (2003) 52(Suppl. 1):A322.
49. AHRÉN B, SÖRHEDE WINZELL M, BURKEY B, HUGHES TE: β-cell expression of a dominant-negative HNF-1α compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur. J. Pharmacol. (2005) 521:164-168.
50. DUTTAROY A, VOELKER F, ZHANG X et al.: The DPP-4 inhibitor vildagliptin increases β cell mass in rodents. Diabetologia (2005) 48(Suppl. 1):A178.
51. RISTIC S, BYIERS S, FOLEY J, HOLMES D: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with Type 2 diabetes: vildagliptin (LAF237) dose response. Diabet. Obes. Metab. (2005) 7:692-698.
52. PRATLEY R, GALBREATH E: Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with Type 2 diabetes (T2DM). Diabetes (2004) 53(Suppl. 2):A83.
53. AHRÉN B, GOMIS R, STANDL E, MILLS D, SCHWEIZER A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with Type 2 diabetes. Diabetes Care (2004) 27:2874-2880.
54. MARI A, SALLAS WM, HE YL et al.: Vildagliptin, a dipeptidyl peptidase IV-inhibitor, improves model-assessed β-cell function in patients with Type 2 diabetes. J. Clin. Endocrinol, Metab. (2005) 90:4888-4894.
55. MARI A, SCHMITZ O, GASTALDELLI A, OESTERGAARD T, NYHOLM B, FERRANNINI E: Meal and oral glucose tests for assessment of β-cell function: model in analysis in normal subjects. Am. J. Physiol. (2002) 283:E1159-E1166.
56. AHRÉN B, HOLST JJ, MARI A: Effects of GLP-1 on the characteristics of β cell function after meal ingestion in humans. Diabetes Care (2003) 26:2860-2864.
57. AHRÉN B, PACINI G, FOLEY JE, SCHWEIZER A: Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with Type 2 diabetes over 1 year. Diabetes Care (2005) 28:1936-1940.
58. MARI A, PACINI G, MURPHY E, LUDVIK B, NOLAN JJ: A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care (2001) 24:539-548.
59. HANSOTIA T, BAGGIO LL, DELMEIRE D et al.: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the gluco-regulatory actions of DPP-IV inhibitors. Diabetes (2004) 53:1326-1335.
60. VILSBOLL T, KRARUP T, MADSBAD S, HOLST JJ: Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia (2002) 45:1111-1119.
61. MEIER JJ, GALLWITZ B, SIEPMANN N et al.: Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. Diabetologia (2003) 46:798-801.
62. NAUCK MA, EL-OUAGHLIDI A: The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia (2005) 48:608-611.
63. HOLST JJ, DEACON CF: Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia (2005) 48:612-615.
64. AHRÉN B: What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia (2005) 48:605-607.
65. AHRÉN B, HUGHES TE: Inhibition of DPP-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice. Endocrinology (2005) 146:2055-2059.
66. LAMBEIR AM, DURINX C, PROOST P, VAN DAMME J, SCHARPÉ S, DE MEESTER I: Kinetic study of the processing by dipeptidyl-peptidase IV /CD26 of neu-ropeptides involved in pancreatic insulin secretion. FEBS Lett. (2001) 507:327-330.
67. ZHU I, TAMVAKOPOULOS C, XIE D et al.: The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-1 (1-38). J. Biol. Chem. (2003) 278:22418-22423.
68. MENTLEIN R: Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul. Pept. (1999) 85:9-24.
69. BARNETT AH: Exenatide. Drugs Today (2005) 41:563-578.
70. HANEFELD M, HERMAN G, MICKEL C et al.: Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with Type 2 diabetes. Diabetologia (2005) 48(Suppl. 1):A287.
71. SCOTT R, HERMAN G, ZHAO P et al.: Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of Type 2 diabetes. Diabetologia (2005) 48(Suppl. 1):A287-A288.
72. TOFT-NIELSEN MB, DAMHOLT MB, MADSBAD S et al.: Determinants of the impaired secretin of glucagon-like peptide-1 in Type 2 diabetic patients. J. Clin. Endocrinol. Metab. (2001) 86:3717-3723.
73. RASK E, OLSSON T, SÖDERBERG S et al.: Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men. Diabetes Care (2001) 24:1640-1645.